Oncology Business Management

The FDA has granted a priority review designation to Lutathera (177Lutetium DOTA-octreotate) as a treatment for patients with gastroenteropancreatic neuroendocrine tumors.

The Department of Health and Human Services has turned down a request to override the patent for prostate cancer drug enzalutamide (Xtandi) so that it can be sold to a broader base of patients at a reduced price.

Many doctors in oncology are pushing themselves to the extreme, and longer workdays have become a fact of life.

Two researchers have challenged the notion that money can be saved by packaging medications in sizes that conform more closely to patient weight and dosing needs.

Cigna's new policy is an extension of a previous Cigna requirement for the use of certified genetic counselors for breast, ovarian, and colorectal cancer genetic tests.

Incoming generic and biosimilar substitutes for dominant, brandname hematology drugs may lead to less costly treatment, but a lot will depend on the quality and supply of these new products,

It seems to be that there is a "minor" disagreement between ASCO and CMS about the approach to address value in cancer care delivery.

Florida Cancer Specialists & Research Institute has honed its merger strategy into a finely tuned regimen that goes from due diligence to planning to implementation and follow-up, all in a period as short as 120 days.

A well-tailored financial counseling program can help a practice minimize exposure to financial risks due to increasing patient responsibility.

The global cost of cancer therapies shot up to $107 billion in 2015, an 11.5% rise from the $100 billion 2014 total for oncology therapeutics and supportive care drugs.

Under direct contracting, a provider signs an agreement with a business or membership organization outlining the care to be provided and the payment scheme, cutting out the insurer completely.

The saying on Wall Street is "sell in May and go away," but there's no detaching from the cliffhanger that CMS has left in the air.

Hematological practices can expect a slate of new generics to replace long-established brand drugs going off patent, as well as new blockbuster blood therapies that will significantly improve the treatment of some malignancies.

The American Board of Internal Medicine has promised to roll out a series of short assessments that could potentially be taken in the privacy of one’s home or office and via an open book exam.

Two researchers have challenged the notion that money can be saved by packaging medications in sizes that conform more closely to patient weight and dosing needs.

The FDA has approved the combination of lenvatinib and everolimus as a treatment for patients with advanced renal cell carcinoma (RCC) following prior anti–angiogeneic therapy